All Evgeny A. Idelevich articles
-
NewsHuman clinical study launched using phage lysin to eliminate staph in the nasal microbiome
A “first-in-human” study with the novel drug candidate HY-133 began on 10 July with the recruitment of clinically healthy volunteers who tested positive for Staphylococcus aureus colonisation of the nose.
-
NewsInnovative phage lysin HY-133 enters phase I clinical study
HYpharm’s innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against Staphylococcus aureus including multi-resistant strains and is intended to combat its colonisation in the nose.
